Pay in 4 interest-free payments of $6.26 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
For gastrointestinal indications, systemic or oral administration is appropriate because the entire gut is the target
Storage: Lyophilized powder frozen at 20 C (4 F)
It is not intended to diagnose, treat, cure, or prevent any disease
Typical daily range: 250500 mcg BPC-157 + 250500 mcg TB-500 (5001,000 mcg total blend) once daily
Triple-hormone-receptor agonist Retatrutide for obesity: Phase 2 trial (48-week study, up to 24% weight loss) American Diabetes Association (2023) ADA Press Release: Novel agent Retatrutide results in substantial weight reduction (83rd Scientific Sessions, Phase 2 data) ADA Meeting News (2023) Phase 2 trial results: benefits of Retatrutide in obesity, type 2 diabetes, NASH (83rd ADA Scientific Sessions coverage) ClinicalTrials.gov Study of Retatrutide (LY3437943) in adults with obesity (NCT04881760
Research shows increased GLUT4 expression leading to better glucose clearance, enhanced insulin receptor sensitivity, and normalized metabolic parameters
US$ 22.08
US$ 26.52
US$ 27.22
US$ 22.55
US$ 26.46
US$ 24.92
